Sun Pharmaceutical Industries Ltd (SUNPHARMA)
₹1,941.10
Mkt cap
₹4.66L Cr
P/E ratio
37.50
P/B
5.58
Div yield
0.82%
ROE
16.00%
ROCE
20.50%
EPS (TTM)
₹51.76
Book value
₹348
52W range
1,563–1,962
Sector
Healthcare
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. [1] It is the largest pharmaceutical company in India. [2]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−1.06% from high₹1,941
₹1,563+24.17% from low₹1,962
Current
₹1,941.10
Prev close
₹1,936.60
Day
+0.23%
Price performance
1D
+0.23%
1W
−0.78%
1M
+4.20%
3M
+19.79%
6M
+20.28%
1Y
+13.95%
YTD
+12.33%
Financials
FRevenue, profit & margin
P/E ratio
37.5×
SUNPHARMA is 11% above the sector median of 33.9×
SUNPHARMA37.5×
Sector median33.9×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10,931 | 11,941 | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | |
| Expenses | 8,129 | 8,609 | 9,013 | 8,904 | 8,948 | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | |
| Operating Profit | 2,802 | 3,332 | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | |
| OPM % | 26% | 28% | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | |
| Other Income | 202 | -118 | 294 | 180 | 504 | 533 | 354 | 149 | 251 | -354 | 470 | 89 | 458 | |
| Interest | 93 | 81 | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | |
| Depreciation | 672 | 651 | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | |
| Profit before tax | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | |
| Tax % | 10% | 19% | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | |
| Net Profit | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | |
| EPS in Rs | 8.27 | 8.43 | 9.90 | 10.52 | 11.06 | 11.82 | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
31 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.04% · closed higher next day 25 of last 60
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 3 Aug '23◦ | 1 Nov '23◦ | 31 Jan '24◦ | 22 May '24◦ | 2 Aug '24◦ | 28 Oct '24◦ | 31 Jan '25◦ | 22 May '25◦ | 31 Jul '25 | 5 Nov '25◦ | 31 Jan '26◦ | 22 May '26 |
| Earnings day | −0.18% | +1.49% | −0.74% | −2.87% | −0.65% | −1.64% | −0.10% | −2.04% | −1.56% | −0.24% | +2.04% | −2.47% |
| +1 day | +1.74% | +2.23% | −0.13% | −3.42% | −1.39% | −2.67% | −0.19% | −2.48% | −6.00% | +0.08% | +6.69% | −2.68% |
| +5 days | −0.76% | +5.38% | +5.72% | −5.21% | +0.13% | −3.97% | +0.34% | −2.39% | −7.81% | +2.80% | +6.85% | −5.01% |
| +15 days | −2.10% | +7.10% | +9.84% | −1.85% | +3.33% | −5.65% | −5.75% | −1.80% | −5.31% | +7.12% | +8.59% | −4.51% |
| +30 days | +0.58% | +12.23% | +9.15% | +1.89% | +7.76% | −4.70% | +0.22% | −2.47% | −7.60% | +3.31% | +12.48% | +0.64% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 5 Per Share | 5.00 | 7 Jul '26 | 7 Jul '26 |
| dividend Interim Dividend - Rs 11 Per Share | 11.00 | 5 Feb '26 | 5 Feb '26 |
Shareholding
Sas of Jun 202654.48%Promoter
Promoters54.48%
FIIs14.54%1.40
DIIs22.06%1.06
Public8.81%0.33
Government0.11%
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,723 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.38 | 1,92,489 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.10 | 1,88,697 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.82 | 1,13,893 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.39 | 1,10,613 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,401 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,559 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Median: 157 Co. | ₹432.05 | 33.93 | 1,970 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts52
PPTJul 2026TranscriptMay 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTDec 2025TranscriptNov 2025RECNov 2025TranscriptSep 2025PPTSep 2025RECSep 2025PPTJul 2025TranscriptMay 2025RECMay 2025TranscriptMar 2025PPTMar 2025RECJan 2025TranscriptNov 2024PPTNov 2024PPTOct 2024PPTSep 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 10h - Organon shareholders approved Sun Pharma’s proposed acquisition on July 24, 2026, pending regulatory approvals.Announcement under Regulation 30 (LODR)-Press Release / Media Release 15 Jul - Sun Pharma gets SAHPRA approval for generic semaglutide in South Africa; launch planned in coming days.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 14 Jul - Sun Pharma to announce Q1 FY2027 results on 31 July 2026, with earnings call at 6:30 pm IST.Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30 June 2026 10 Jul - Board meeting on 31 July 2026 to approve Q1 FY27 results; trading window closed until 2 August 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 7 Jul